Impairment of platelet retention rate in patients with severe aortic valve stenosis  by Takahashi, Nobuyuki et al.
OI
v
N
H
T
Y
a
b
c
a
A
R
R
A
A
K
A
P
v
I
t
I
u
n
O
a
s
e
s
t
0
hJournal of Cardiology 62 (2013) 171–175
Contents lists available at SciVerse ScienceDirect
Journal  of  Cardiology
jo ur nal home page: www.elsev ier .com/ locate / j j cc
riginal  article
mpairment  of  platelet  retention  rate  in  patients  with  severe  aortic
alve  stenosis
obuyuki  Takahashi  (MD,  PhD)a,∗, Kazuaki  Tanabe  (MD,  PhD,  FJCC)a,
iroyuki  Yoshitomi  (MD)a,  Tomoko  Adachi  (MD)a,  Saki  Ito  (MD)a,
akashi  Sugamori  (MD,  PhD)a, Akihiro  Endo  (MD,  PhD)a,
utaka  Ishibashi  (MD,  PhD,  FJCC)b, Teiji  Oda  (MD,  PhD)c
Fourth Department of Internal Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo City, Shimane 693-8501, Japan
Department of General Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo City, Shimane 693-8501, Japan
Department of Cardiovascular Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo City, Shimane 693-8501, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 4 April 2012
eceived in revised form 22 March 2013
ccepted 11 April 2013
vailable online 2 June 2013
eywords:
ortic valve stenosis
latelet retention rate
on Willebrand factor
a  b  s  t  r  a  c  t
Background:  Recent  reports  revealed  the  presence  of acquired  von  Willebrand  syndrome  type 2A in
patients  with  aortic  valve  stenosis  (AS).  von  Willebrand  factor  (vWF)  has  been  shown  to  play a  vital  role
in  platelet  adhesion.  Therefore,  we  measured  the  platelet  retention  rates,  which  reﬂect  platelet  adhesion,
in patients  with  severe  AS.
Methods:  In addition  to  echocardiography,  routine  blood  screening  tests  were  performed  and  the  platelet
retention  rates  were  measured  using  collagen-coated  bead  columns  in 21 patients  with  severe  AS and  in
21  control  subjects.
Results: Patients  with  severe  AS showed  the  maximum  aortic  valve  pressure  gradients  of
110.9  ±  22.7  mmHg,  and  effective  oriﬁce  areas  of  0.59  ± 0.20  cm2.  The  results  of  routine  blood  tests  in
patients  with  severe  AS  were  comparable  to those  of control  subjects;  however,  the  platelet  retention
rates  in  the  AS  patients  (7.3 ±  5.0%)  were  signiﬁcantly  lower  than  those  in control  subjects  (30.5  ± 11.8%,
p  <  0.001).  A  signiﬁcant  negative  correlation  was  observed  between  maximum  aortic  valve  pressure  gra-
dients and platelet  retention  rates  (r =  −0.81,  p < 0.001).  In 8 patients  with  severe  AS, the  platelet  retention
rates  increased  from  5.8  ±  3.6%  to  16.0 ±  2.4%  after  aortic  valve  replacement  (p < 0.001).
Conclusion:  These  ﬁndings  suggest  that  impairment  of platelet  retention  rate  is seen  in  almost  all  patients
with  severe  AS. Clinicians  should  be  aware  of  the  possibilities  of vWF-mediated  platelet  dysfunction  and
ients  
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Sclerosis, calciﬁcation, and stenosis of the aortic valve are
he most common acquired valvular lesions in elderly patients.
ncreased life expectancy has resulted in an increase in the pop-
lation of elderly people, with a corresponding increase in the
umber of patients with such degenerative aortic valve diseases.
tto et al. reported that 29% of individuals older than 65 years have
ortic valve sclerosis, and 2% of this population has aortic valve
tenosis (AS) [1]. The rate of AS progression may  be more rapid in
lderly patients [2], and some reports demonstrate that hemodialy-
is, serum calcium, hypertension, and hyperlipidemia among other
hings are associated with the progression of AS [3,4].
∗ Corresponding author. Tel.: +81 853 20 2206; fax: +81 853 20 2201.
E-mail address: yukihiro@med.shimane-u.ac.jp (N. Takahashi).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.04.002with  severe  AS.
anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
In 1958, Heyde ﬁrst reported that 10 patients with AS had
gastrointestinal bleeding of unknown cause [5]. In the same
year, Goldman reviewed 37,423 patients and showed a 3-fold
higher incidence of gastrointestinal bleeding than the predicted
incidence in patients with AS [6]. The precise mechanism under-
lying the link between AS and gastrointestinal bleeding tendency
was unknown for a long time. Vincentelli et al. demonstrated
that the high-molecular-weight von Willebrand multimers were
reduced in proportion to the severity of AS, and valve replace-
ment could restore the impaired distribution of the multimers [7].
Nowadays, the relationship between AS, acquired von Willebrand
syndrome type 2A (deﬁciency in high-molecular-weight von Wille-
brand multimers), and anemia due to gastrointestinal bleeding
from intestinal angiodysplasia is known as Heyde syndrome [8].
However, patients with severe AS usually have normal results in
routine blood screening tests. Therefore, many clinicians are prob-
ably unaware of the abnormal hemostasis in patients with severe
AS.
vier Ltd. All rights reserved.
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Tokyo, Japan). A collagen-coated bead column was  connected to
the syringe, and the syringes were placed in the holder of an injec-
tion pump. The blood samples in the syringes were passed through
the collagen-coated bead columns at a ﬁxed ﬂow rate of 1.5 ml/30 s.
Table 1
Comparison of baseline characteristics of study patients and control subjects.
Severe AS group
(n = 21)
Control subjects
(n = 21)
p-Value
Age (years) 75.2 ± 10.2 69.0 ± 8.6 0.037
Sex  (female/male) 13/8 9/12 0.217
Hypertension 8 16 0.013
Diabetes mellitus 3 1 0.293
Hyperlipidemia 8 8 1.000
Medication use (n)
ACE-I/ARB 7 8 0.747
Ca-blocker 6 11 0.01572 N. Takahashi et al. / Journal
The interaction between von Willebrand factor (vWF) and
latelet glycoprotein (GP) Ib plays a critical role in the initial
hase of platelet adhesion, particularly under high shear stress
9]. Until recently, quantiﬁcation of platelet adhesiveness was  per-
ormed using glass-bead columns, and the methods for quantitative
stimation were developed and modiﬁed [10]. The methods princi-
ally measured the retention of platelets during passage of whole
lood through glass-bead columns. Now, spherical copolymer
lastic beads coated with porcine type I collagen have been devel-
ped and are being used for the measurement of platelet retention
11]. Because collagen is a major subendothelial component, mea-
urement of platelet adhesion using this assay is expected to reﬂect
hysiologic platelet responses more accurately than the glass-bead
olumns. vWF  might affect the platelet retention rates measured
sing the collagen-coated bead columns. Ideguchi et al. reported
hat 62% of platelet adhesion to the collagen-coated bead columns
as inhibited by the antibody of vWF  (MAS534p), which inhibits
PIb binding site of vWF  [12]. We  previously reported a patient
ith Heyde syndrome who showed normal results of almost all rou-
ine blood screening tests, but a signiﬁcant decrease in the platelet
etention rate measured using this collagen-coated bead column
ethod and the deﬁciency in high-molecular-weight von Wille-
rand multimers by gel electrophoresis [13].
Thus, in this study, we examined whether the platelet retention
ates in patients with severe AS are lower than those in control sub-
ects and whether platelet retention rates change after aortic valve
eplacement (AVR). Additionally, we evaluated the relationship
etween platelet retention rate and aortic valve pressure gradient
s an indicator of shear stress.
ethods
tudy patients
Between August 2009 and December 2012, 21 consecutive
atients (8 men  and 13 women; mean ± SD age, 75.2 ± 10.2 years)
eferred to Shimane University Hospital for evaluation of severe AS
ere enrolled in the study.
The diagnosis of severity was made according to the European
ssociation of Echocardiography/American Society of Echocardiog-
aphy guidelines [14]. Thus, severe AS was deﬁned as an aortic valve
rea less than 1.0/cm2 or a mean gradient greater than 40 mmHg,
s determined by Doppler echocardiography.
In addition, 21 control subjects who visited our hospital for fur-
her medical examination of hypertension and electrocardiogram
bnormalities (12 men  and 9 women; mean ± SD age, 69.0 ± 8.6
ears) were enrolled in the study.
The exclusion criteria were personal or family history of genetic
leeding disorder or thrombotic disorder, platelet counts <100,000
r >450,000 mm–3, serum creatinine levels >2.0 mg/dl, acute infec-
ious disease, autoimmune disorders, neoplasm, viral hepatitis, or
igniﬁcant valve diseases other than AS. Further, patients receiving
ny antiplatelet or anticoagulant treatment and steroids or non-
teroidal anti-inﬂammatory drugs at the time of evaluation were
xcluded from the present study.
Baseline characteristics of patients with severe AS and control
ubjects are shown in Table 1. Patients with severe AS (75.2 ± 10.2
ears) were signiﬁcantly older than control subjects (69.0 ± 8.6
ears, p = 0.037). There were no signiﬁcant differences between the
roups regarding the prevalence of diabetes mellitus and hyperlipi-
emia, and the administration of angiotensin-converting enzyme
nhibitors/angiotensin receptor blockers, -blockers, and statins.
he numbers of patients with hypertension and receiving admin-
stration of a Ca antagonist were much higher among the control
ubjects (p = 0.012, 0.015, respectively).diology 62 (2013) 171–175
Written informed consent was  obtained from each patient and
control subjects.
Echocardiographic evaluation
Transthoracic echocardiography was performed using a Philips
iE33 echocardiographic system (Andover, MA,  USA) to assess the
hemodynamic performance of the aortic valve in patients with
severe AS and in control subjects on the same day or within a few
days of the platelet retention tests. The mean and peak transvalvu-
lar pressure gradients were calculated using the modiﬁed Bernoulli
equation, and the effective oriﬁce area was calculated using the
continuity equation [15].
Blood collection and laboratory assays
Blood samples were collected for simultaneous assess-
ment of platelet retention rates, platelet counts, prothrombin
time-international normalized ratio (PT-INR), activated partial
thromboplastin time (APTT), and ﬁbrinogen levels.
In the present study, we performed the multimers analysis of
vWF  by gel electrophoresis in 5 patients with severe AS. Addi-
tionally, we measured the activities of the vWF-cleaving protease
ADAMTS 13 (a disintegrin and metalloproteinase with throm-
bospondin type 1 motif, member 13) which targets the A2 domain
of vWF  and speciﬁcally cleaves the protein Tyr1605-Met1606 [16],
in 5 patients with severe AS.
Fasting-state blood samples were obtained from all patients
with severe AS and from control subjects at 10:00 am.  Blood
samples were drawn from the antecubital vein under mini-
mal  tourniquet pressure using a sterile 21-gauge needle syringe.
All parameters were measured by routine laboratory techniques
blinded to the origin of the sample.
Measurement of platelet retention rate
In an air conditioned room at a temperature of 25–26 ◦C, the
platelet retention rate was  measured in all patients with severe
AS and in control subjects according to the methods described
by Kaneko et al. [11]. Brieﬂy, co-polymer plastic beads (diameter,
0.4–0.6 mm)  coated with porcine type I collagen were packed into
a polyvinyl tubing with an internal diameter of 2 mm and length
of 80 mm.  These Pla-Bead columns are disposable and commer-
cially available, and they are distributed by ISK Co., Ltd., Tokyo,
Japan. The whole blood samples were mixed by twirling and 1.5 ml
of the sample was  drawn into a plastic syringe (2.5 ml)  (Terumo,-blocker 1 3 0.293
Statin 8 8 1.000
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
AS,  aortic valve stenosis.
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The samples before and after passage through the columns were
ollected into plastic tubes containing EDTA, and platelet counts
ere measured by an automated hematology analyzer, XE-2100
Sysmex, Kobe, Japan). Platelet retention rates (%) were calculated
s follows: 100[(platelet count before passage) − (platelet count
fter passage)]/(platelet count before passage).
tatistical analysis
Statistical analysis was performed using SPSS version 18.0
Chicago, IL, USA). Values are expressed as the mean ± standard
eviation (SD). Comparisons between the 2 groups were per-
ormed using Mann–Whitney U test, and Wilcoxon signed-rank
est was used to compare before and after AVR. The relation-
hip between continuous variables was examined by Spearman’s
ank-correlation test. A p-value < 0.05 was considered statistically
igniﬁcant.
esults
Echocardiography data and laboratory parameters of patients
ith severe AS and control subjects are shown in Table 2.
In patients with severe AS, the maximum aortic valve pressure
radient was 110.9 ± 22.7 mmHg, the mean aortic valve pressure
radient was 66.4 ± 15.5 mmHg, and effective oriﬁce area calcu-
ated using the continuity equation was 0.59 ± 0.20 cm2.
In both patients with severe AS and in control subjects, the val-
es of the routine blood screening tests (platelet counts, PT-INR,
PTT, and ﬁbrinogen) were within normal limits, and no signiﬁcant
ifference was observed between the 2 groups except for PT-INR.
In 5 patients with severe AS, the multimers analysis of vWF  by
el electrophoresis revealed loss of the large multimers of vWF
Fig. 1). Additionally, the activities of ADAMTS 13 in all 5 of these
atients were within normal limits (87.8 ± 10.1%, normal 70–120%).
able 2
omparison of echocardiographic and blood screening data of study patients and control
Severe AS group(n =
Echocardiographic data
Maximum transvalvular gradient (mmHg) 110.9 ± 22.7 
Mean  transvalvular gradient (mmHg) 66.4 ± 15.5 
Aortic valve area (cm2) 0.59 ± 0.20 
Laboratory parameters
Platelet counts (×10/mm3) 20.4 ± 4.6 
PT-INR 0.96 ± 0.07 
APTT  (s) 33.2 ± 4.6 
Fibrinogen (mg/dl) 305.7 ± 78.5 
S, aortic valve stenosis; PT-INR, prothrombin time-international normalized ratio; APTT
ig. 1. The multimers analysis of von Willebrand factor by gel electrophoresis in 5 patien
S.  L, large multimer; M, middle multimer; S, small multimer; SS, very small multimer.aortic valve stenosis (AS).
The platelet retention rate varied from 13.5% to 59.6% in con-
trol subjects and the mean value was 30.5 ± 11.8%. However, the
platelet retention rates in patients with severe AS (7.3 ± 5.0%) were
signiﬁcantly lower than those in control subjects (30.5 ± 11.8%,
p < 0.001, Fig. 2). In the linear regression analysis on the correla-
tion with the platelet retention rates and maximum aortic valve
pressure gradients, we have additionally investigated 4 mild-
moderate AS patients in order to increase the accuracy of our
research. In the 4 patients with mild-moderate AS, the maximum
aortic valve pressure gradients were 42, 43, 66, and 68 mmHg, and
the platelet retention rates were 30.9%, 29.0%, 17.2%, and 15.6%,
respectively. The linear regression analysis showed that the platelet
retention rate had a signiﬁcant and negative correlation with max-
imum aortic valve pressure gradient (r = −0.81, p < 0.001, Fig. 3).
 subjects.
 21) Control subjects(n = 21) p-Value
9.0 ± 5.3 <0.001
4.8 ± 3.0 <0.001
2.68 ± 0.54 <0.001
20.2 ± 2.7 0.819
0.91 ± 0.06 0.013
30.9 ± 3.1 0.067
277.6 ± 47.0 0.178
, activated partial thromboplastin time.
ts with severe aortic valve stenosis (AS). N, control subject; A, patient with severe
174 N. Takahashi et al. / Journal of Car
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iig. 3. Linear regression analysis on the correlation with the platelet retention rates
nd maximum aortic valve pressure gradient.
In this study, 2 of the 21 patients with severe AS showed gas-
rointestinal bleeding from angiodysplasia.
Receiver operating characteristic curves were constructed to
xplore the diagnostic utility of the platelet retention rate for severe
S. Estimates of the area under the curve showed the platelet reten-
ion rate to be good for detecting severe AS, with an area under the
urve of 0.986. In an exploratory analysis of possible cut-off points
or the platelet retention rate, a threshold of 14.3% demonstrated
5% sensitivity, and 91% speciﬁcity for the detection of severe AS.
In the present study, we had the opportunity to re-evaluate
 patients with severe AS after they had undergone AVR. We
gain measured the platelet retention rate and performed echocar-
iography 154 ± 142 days after AVR. The maximum aortic valve
ressure gradients in these patients had signiﬁcantly decreased
rom 109.6 ± 21.9 mmHg  to 50.9 ± 19.2 mmHg  after AVR (p < 0.001),
nd the platelet retention rates had signiﬁcantly increased from
.8 ± 3.4% to 16.0 ± 2.4% after AVR (p < 0.001, Fig. 4).
iscussion
To our knowledge, this is the ﬁrst report on the platelet reten-
ion rates in patients with severe AS. Although the values of routine
lood screening tests in patients with severe AS were within nor-
al  limits, the platelet retention rates in these patients were
igniﬁcantly lower than those in control subjects. The platelet
etention rate had a signiﬁcant and negative correlation with
aximum aortic valve pressure gradient. Additionally, platelet
etention rates signiﬁcantly improved after AVR.
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P < 0.001
ig. 4. The platelet retention rates before and after aortic valve replacement (AVR)
n  patients with severe aortic valve stenosis.diology 62 (2013) 171–175
vWF  is a plasma glycoprotein that mediates shear-dependent
platelet adhesion to the subendothelium and the subsequent
platelet-platelet interactions. vWF  binds to the platelet recep-
tor glycoprotein Ib/IX and to injured vessel walls by interacting
with collagen. vWF  is synthesized in endothelial cells and
megakaryocytes as an ultra-large molecule. vWF  multimers
secreted into blood can be >20 million Da in mass and 4 m
in length. Upon secretion, molecular size of vWF  is reduced by
ADAMTS-13. ADAMTS-13 cleaves the Tyr1605-Met1606 peptide
bond within the vWF  A2 domain thus generating smaller multimers
and proteolysis fragments. The larger multimers of vWF  are more
likely to bind to platelets and collagen, and to promote platelet
adhesion in circulating blood [16].
Tsai et al. demonstrated that shear stress enhances the proteo-
lysis of vWF  multimers in normal plasma [17]. Recent experimental
reports showed that high shear stress can alter the structure of
the vWF  molecule and induce unfolding of the A2 domain which
is sensitive to the action of ADAMTS-13 [18,19]. Vincentelli et al.
[7] reported that many patients with severe AS have acquired
von Willebrand disease type 2A. vWF  multimer is subjected to
high ﬂuid shear stress when is passes through the stenosed aortic
valve and that renders the multimers susceptible to cleavage by
ADAMTS-13, and loss of the largest vWF  multimers leads to impair-
ment of primary hemostasis and results in bleeding tendency. In
the present study, the activities of ADAMTS 13 in all 5 severe AS
patients were within normal limits. Recent reports demonstrated
[18,19] that conformational change of high-molecular-weight von
Willebrand multimers is induced by high shear stress, exposing
sites on A2 domains that can be cleaved by ADAMTS-13. Addition-
ally, Loscalzo reported that it was not ADAMTS-13 activity itself
but the conformation of the vWF  substrate that regulates its pro-
teolysis [20]. Therefore, in the present study, these conformational
mechanisms would presumably be responsible for the decrease
in high-molecular-weight von Willebrand multimers in patients
with severe AS.
However, in the present study, almost all patients with severe AS
showed normal results of routine blood screening tests. Therefore,
many clinicians are probably unaware of the abnormal hemosta-
sis in patients with severe AS. Actually, Goldman showed a 3-fold
higher incidence of gastrointestinal bleeding than the predicted
incidence in patients with AS [6]. Vincentelli et al. reported that
9 (21.4%) of 42 patients with severe AS had at least one episode of
abnormal bleeding, usually skin or mucosal bleeding [7]. Schodel
et al. reported severe recurrent epistaxis in 2 patients with severe
AS [21]. Also in our study, 2 of the 21 patients with severe
AS showed gastrointestinal bleeding from angiodysplasia. Their
platelet retention rates were 7.7% and 8.4%, respectively. However,
in the present study, the numbers of such patients were small.
Therefore, further studies are required to clarify the precise cor-
relation between the platelet retention rate and the occurrence of
bleeding events.
In 2003, Kaneko et al. demonstrated a new, simple assay for
determining platelet function using a column of collagen-coated
beads. The platelet retention rate in the column principally repre-
sents platelet adhesion and following aggregation at the injured
artery with high reproducibility [11]. The interaction between vWF
and GP Ib plays a critical role in the initial phase of platelet adhe-
sion, particular under high shear stress [9]. Additionally, Ideguchi
et al. reported that 62% of platelet adhesion to collagen-coated
bead columns was inhibited by the antibody of vWF  (MAS534p),
which inhibits GPIb binding site of vWF  [12]. Therefore, we
think that impairment of platelet retention rate might reﬂect
vWF-mediated platelet dysfunction in patients with severe AS. In
the present study, we showed that the platelet retention rate had
a signiﬁcantly negative correlation with maximum transvalvu-
lar pressure gradient. These ﬁndings are also consistent with
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replacement in patients with Heyde syndrome. J Thorac Cardiovasc SurgN. Takahashi et al. / Journal 
incentelli’s ﬁnding that the percentages of the highest molecular
eight vWF  multimers were negatively correlated with the mean
ransvalvular gradient in patients with severe AS. Accordingly,
ecrease or loss of high-molecular weight vWF  multimers might
nduce the impairment of the platelet retention rate.
In the present study, we showed that the platelet retention rates
igniﬁcantly improved after AVR. Several reports showed that loss
f the high molecular weight vWF  multimers improve after AVR
7,22]. Recently, Thompson et al. showed that more than 75% of
S patients with gastrointestinal bleeding due to angiodysplasia
ave no bleeding symptom after AVR [23]. Thus, abnormal bleed-
ngs such as gastrointestinal bleeding due to angiodysplasia may  be
onsidered as an indication for AVR in patients with signiﬁcant AS.
In the present study, the platelet retention rates improved after
VR, but, were not equal to those of the control subjects. We  specu-
ate that two factors might have affected this result. First, the maxi-
um  aortic valve pressure gradients did not completely normalize
fter AVR (decreasing from 109.6 to 50.9 mmHg), such that the
esidual pressure gradients might have impaired restoration of the
latelet retention rates. Second, anticoagulant and/or antiplatelet
gents were prescribed to 7 patients after AVR. These factors might
ave reduced the recoveries of platelet retention rates.
In various tests for acquired vWF  deﬁciency, gel electrophore-
is of vWF  is most sensitive [8]. However, gel electrophoresis of
WF  is complicated and requires cost and time. By contrast, the
dvantage of the collagen-coated beads column method over the
ther methods includes easy procedure and low cost of instru-
ents. Measurement of the platelet retention rate using a column
f collagen-coated beads might be clinically useful for monitoring
he vWF-mediated platelet dysfunction in patients with severe AS.
tudy limitations
Our study has several limitations. First, we enrolled a very small
umber of patients in this study, because of the numerous and strict
xclusion criteria. Thus, this assay method should be evaluated in
 larger number of patients for veriﬁcation of its clinical utility.
Our data showed wide variability in the platelet retention rate
n control subjects. However, the wide variability of the platelet
ctivity is consistent with the data from the other platelet reten-
ion rate test. Cuyun-Lira et al. showed that the platelet retention
ate measured using collagen-coated bead columns varied from
6% to 78% in 18 healthy individuals and the mean ± SD value
as 38.7% ± 16.0% [24]. On the basis of high reproducibility of the
latelet retention assay [11], the wide variability of the platelet
etention rate may  reﬂect the individual variability itself but not
he methodological variability.
In the present study, the patients with severe AS were sig-
iﬁcantly older than the control subjects (p = 0.037). Conversely,
he numbers of patients with hypertension and receiving adminis-
ration of a Ca antagonist were much higher among the control
ubjects than the AS patients (p = 0.012, p = 0.015, respectively).
owever, neither age-related changes in the platelet retention rate,
or effects of hypertension and Ca antagonists on this rate have
een reported to date. Further studies with a larger population of
ealthy individuals of various ages and patients with hypertension
re required.
Additionally, we investigated only 4 mild-moderate AS patients
n the present study. Therefore, further studies focusing on the
ild-intermediate AS patients are required to clarify the correla-
ion between the platelet retention rate and the severity of AS.onclusion
Our ﬁndings suggest that the platelet retention rate is reduced
n almost all patients with severe AS. In patients with severe
[diology 62 (2013) 171–175 175
AS, abnormal bleedings such as gastrointestinal angiodysplasia
may  be not a coincidence but a consequence of the loss of the
high-molecular-weight multimers of vWF  in the plasma. Clinicians
should be aware of the vWF-mediated platelet dysfunction and
bleeding tendency in patients with severe AS.
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